Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study

Area of Science:

• Veterinary Oncology
• Molecular Biology
• Toxicology

Background:

• Mammary tumors are common in intact female dogs, necessitating targeted therapies.
• Reengineered Bacillus anthracis toxin targets tumor cells expressing specific enzymes (urokinase plasminogen activators and metalloproteinases).
• Previous research demonstrated efficacy against canine oral melanoma and osteosarcoma.

Purpose of the Study:

• To evaluate the efficacy of reengineered anthrax toxin on canine mammary tumor cell lines.
• To assess the toxin's selectivity for neoplastic versus non-neoplastic mammary epithelial cells.

Main Methods:

• Treatment of five canine neoplastic epithelial cell lines (adenocarcinomas, adenoma) and one non-neoplastic mammary epithelial cell line with the reengineered toxin.
• Quantification of cell viability using MTT assay.
• Determination of half-maximal inhibitory concentration (IC50) values to assess sensitivity.

Main Results:

• One mammary adenocarcinoma and one mammary adenoma cell line exhibited significantly reduced viability post-treatment.
• The non-neoplastic canine mammary epithelial cell line demonstrated resistance to the toxin.
• Sensitivity was defined as an IC50 value below 5000 ng/ml.

Conclusions:

• The reengineered anthrax toxin demonstrates targeted cytotoxicity against canine mammary neoplasms.
• This toxin represents a potential targeted therapy for canine mammary tumors.
• The treatment shows promise for preserving normal canine mammary epithelial cells.